Literature DB >> 3159710

Comparative in-vitro activity of ciprofloxacin against non-fermenters.

M O Husson, D Izard, L Bouillet, H Leclerc.   

Abstract

The in-vitro activity of ciprofloxacin, a quinolone-carboxylic acid derivative, was compared with those of carbenicillin, azlocillin, cefsulodin, ceftazidime, tobramycin and amikacin against 187 non-fermenters. Only one of the 131 strains of Pseudomonas spp. was not inhibited by 1 mg/l of ciprofloxacin, while these isolates appeared highly resistant to carbenicillin, azlocillin and cefsulodin. Ciprofloxacin was also the best agent against Flavobacterium, Alcaligenes faecalis and Acinetobacter calcoaceticus with MIC90's respectively of 0.5, 4 and 8 mg/l. This new compound appeared bactericidal, and we found a small or no inoculum effect with ciprofloxacin.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3159710     DOI： 10.1093/jac/15.4.457

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  15 in total

1.  Clinical and microbiological analysis of bloodstream infections caused by Chryseobacterium meningosepticum in nonneonatal patients.

Authors:  Pen-Yi Lin; Chishih Chu; Lin-Hui Su; Chung-Tsui Huang; Wen-Ya Chang; Cheng-Hsun Chiu
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.

Authors:  G Phillips; L W Fleming; W K Stewart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

3.  Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

Authors:  J C Chang; P R Hsueh; J J Wu; S W Ho; W C Hsieh; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 7.  The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

Authors:  O C Tablan; W J Martone; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

Review 8.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

9.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.

Authors:  S Esposito; D Galante; D Barba; W Bianchi; R Gagliardi; R Giusti
Journal:  Infection       Date:  1988       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.